LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative, Metastatic Breast Cancer
Frontiers | Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred | Scientific Reports
Updates in endocrine therapy for metastatic breast cancer | Cancer Biology & Medicine
BREAST CANCER - Daily Reporter
Chemotherapy Statistics | Success Rate & Cost
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Abemaciclib plus aromatase inhibitor in advanced breast cancer
Rethinking neoadjuvant chemotherapy for breast cancer | The BMJ
Navigating HR+/HER2- Early Breast Cancer Treatment Strategies - Cancer Therapy Advisor
PDF) Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
Cancer treatment and survivorship statistics, 2022 - Miller - 2022 - CA: A Cancer Journal for Clinicians - Wiley Online Library
Figure 1 from Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. | Semantic Scholar
Adjuvant Chemotherapy Improves Prostate Cancer Survival - NCI
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes | Annals of Surgical Oncology
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia | Scientific Reports
Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older - Trevor Jolly, Grant R Williams, Ellen Jones, Hyman B Muss, 2012
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial | npj Breast Cancer
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy | Breast Cancer Research | Full Text
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Chemotherapy With Endocrine Therapy Shows Clinical Benefit With Improved Survival in Breast Cancer
